{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:46:48Z","timestamp":1773103608464,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1U01AI155300-01A1"],"award-info":[{"award-number":["1U01AI155300-01A1"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite treatment with highly effective antimalarial drugs, malaria annually claims the lives of over half a million children under 5-years of age in sub-Saharan Africa. Cerebral malaria (CM), defined as <jats:italic>Plasmodium falciparum<\/jats:italic> infection with coma, is the severe malaria syndrome with the highest mortality. Studies in the CM mouse model suggest that a T cell-mediated response underlies CM pathology, opening a new target for therapy in humans. This trial aims to establish the preliminary safety of one such novel therapy, the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this phase I\/IIa dose-escalation clinical trial, a single dose of intravenous (IV) DON is administered to three participants groups\u2014healthy adults and adults with uncomplicated malaria, then pediatric participants with CM\u2014to primarily assess safety. The secondary objective of this trial is to assess pharmacokinetics of DON over a range of doses. The open-label adult portion of the trial enrolls 40 healthy adults concurrently with 40 adults with uncomplicated malaria. Cohorts of 10 participants receive a single\u00a0IV dose of\u00a0DON with doses escalating\u00a0between cohorts from 0.1\u00a0mg\/kg, 1.0\u00a0mg\/kg, 5.0\u00a0mg\/kg, to 10\u00a0mg\/kg. Following subsequent safety review, a randomized, double-blind, and placebo-controlled pediatric study enrolls 72 participants aged 6\u00a0months to 14\u00a0years with CM. The pediatric portion of the study minimally spans three malaria seasons including a planned interim analysis after 50% of pediatric enrollments. The first half of pediatric participants receive DON 0.1\u00a0mg\/kg, 1.0\u00a0mg\/kg, or placebo. Dosing for the second half of pediatric participants is informed by the safety and preliminary efficacy results of those previously enrolled. The pediatric portion of the study has an exploratory outcome evaluating the preliminary efficacy of DON. Efficacy is assessed by diagnostics predictive of CM outcome: electroencephalography (EEG), magnetic resonance imaging (MRI), and transcranial doppler (TCD), measured before and after DON administration. All participants with malaria receive standard of care antimalarials in accordance with local guidelines, regardless of study drug dose group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This preliminary safety and efficacy study evaluates DON, a candidate\u00a0adjunctive therapy for pediatric CM. If results support DON preliminary safety and efficacy, follow-up phase II and III clinical trials will be indicated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This trial was registered on ClinicalTrials.gov on 28 July 2022 (NCT05478720).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07808-w","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T08:02:03Z","timestamp":1706256123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["DON in pediatric cerebral malaria, a phase I\/IIA dose-escalation safety study: study protocol for a clinical trial\u00a0"],"prefix":"10.1186","volume":"25","author":[{"given":"Nginache","family":"Nampota-Nkomba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osward M.","family":"Nyirenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Mallewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamikani","family":"Chimalizeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nettie","family":"Dzabala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathangi","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew B.","family":"Laurens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole F.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-3437","authenticated-orcid":false,"given":"Susan K.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-8971","authenticated-orcid":false,"given":"Brittany A.","family":"Riggle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5815-0691","authenticated-orcid":false,"given":"Douglas G.","family":"Postels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"7808_CR1","unstructured":"World malaria report 2022. Geneva: World Health Organization; 2022. Licence:CC BY-NC-SA 3.0 IGO. https:\/\/www.who.int\/publications\/i\/item\/9789240064898."},{"issue":"6","key":"7808_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000290","volume":"7","author":"SI Hay","year":"2010","unstructured":"Hay SI, Okiro EA, Gething PW, Patil AP, Tatem AJ, Guerra CA, et al. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med. 2010;7(6): e1000290.","journal-title":"PLoS Med"},{"key":"7808_CR3","first-page":"7","volume":"19 Suppl 1","author":"World Health Organization (WHO)","year":"2014","unstructured":"World Health Organization (WHO). Severe malaria. Trop Med Int Health. 2014;19 Suppl 1:7\u2013131.","journal-title":"Trop Med Int Health."},{"issue":"5","key":"7808_CR4","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1016\/j.ajpath.2011.01.016","volume":"178","author":"K Dorovini-Zis","year":"2011","unstructured":"Dorovini-Zis K, Schmidt K, Huynh H, Fu W, Whitten RO, Milner D, et al. The neuropathology of fatal cerebral malaria in Malawian children. Am J Pathol. 2011;178(5):2146\u201358.","journal-title":"Am J Pathol"},{"issue":"11","key":"7808_CR5","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/j.1365-3156.2005.01505.x","volume":"10","author":"G Enwere","year":"2005","unstructured":"Enwere G. A review of the quality of randomized clinical trials of adjunctive therapy for the treatment of cerebral malaria. Trop Med Int Health. 2005;10(11):1171\u20135.","journal-title":"Trop Med Int Health"},{"issue":"6","key":"7808_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1056\/NEJM198202113060601","volume":"306","author":"DA Warrell","year":"1982","unstructured":"Warrell DA, Looareesuwan S, Warrell MJ, Kasemsarn P, Intaraprasert R, Bunnag D, et al. Dexamethasone proves deleterious in cerebral malaria. A double-blind trial in 100 comatose patients. N Engl J Med. 1982;306(6):313\u20139.","journal-title":"N Engl J Med."},{"key":"7808_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1475-2875-6-138","volume":"6","author":"B Namutangula","year":"2007","unstructured":"Namutangula B, Ndeezi G, Byarugaba JS, Tumwine JK. Mannitol as adjunct therapy for childhood cerebral malaria in Uganda: a randomized clinical trial. Malar J. 2007;6:138.","journal-title":"Malar J"},{"issue":"3","key":"7808_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/adc.76.3.219","volume":"76","author":"CR Newton","year":"1997","unstructured":"Newton CR, Crawley J, Sowumni A, Waruiru C, Mwangi I, English M, et al. Intracranial hypertension in Africans with cerebral malaria. Arch Dis Child. 1997;76(3):219\u201326.","journal-title":"Arch Dis Child"},{"issue":"4","key":"7808_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/cid\/cir405","volume":"53","author":"S Mohanty","year":"2011","unstructured":"Mohanty S, Mishra SK, Patnaik R, Dutt AK, Pradhan S, Das B, et al. Brain swelling and mannitol therapy in adult cerebral malaria: a randomized trial. Clin Infect Dis. 2011;53(4):349\u201355.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"7808_CR10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1086\/427505","volume":"40","author":"K Maitland","year":"2005","unstructured":"Maitland K, Pamba A, English M, Peshu N, Marsh K, Newton C, et al. Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin Infect Dis. 2005;40(4):538\u201345.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"7808_CR11","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1371\/journal.pctr.0010021","volume":"1","author":"S Akech","year":"2006","unstructured":"Akech S, Gwer S, Idro R, Fegan G, Eziefula AC, Newton CRJC, et al. Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. PLoS Clin Trials. 2006;1(5):e21.","journal-title":"PLoS Clin Trials"},{"issue":"2","key":"7808_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/infdis\/158.2.325","volume":"158","author":"SL Hoffman","year":"1988","unstructured":"Hoffman SL, Rustama D, Punjabi NH, Surampaet B, Sanjaya B, Dimpudus AJ, et al. High-dose dexamethasone in quinine-treated patients with cerebral malaria: a double-blind, placebo-controlled trial. J Infect Dis. 1988;158(2):325\u201331.","journal-title":"J Infect Dis"},{"issue":"3","key":"7808_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2249.1992.tb05851.x","volume":"90","author":"TE Taylor","year":"1992","unstructured":"Taylor TE, Molyneux ME, Wirima JJ, Borgstein A, Goldring JD, Hommel M. Intravenous immunoglobulin in the treatment of paediatric cerebral malaria. Clin Exp Immunol. 1992;90(3):357\u201362.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"7808_CR14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/infdis\/174.5.1091","volume":"174","author":"MB van Hensbroek","year":"1996","unstructured":"van Hensbroek MB, Palmer A, Onyiorah E, Schneider G, Jaffar S, Dolan G, et al. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J Infect Dis. 1996;174(5):1091\u20137.","journal-title":"J Infect Dis"},{"issue":"5","key":"7808_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/infdis\/171.5.1317","volume":"171","author":"G Di Perri","year":"1995","unstructured":"Di Perri G, Di Perri IG, Monteiro GB, Bonora S, Hennig C, Cassatella M, et al. Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. J Infect Dis. 1995;171(5):1317\u201322.","journal-title":"J Infect Dis"},{"key":"7808_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/1475-2875-9-368","volume":"9","author":"B Lell","year":"2010","unstructured":"Lell B, K\u00f6hler C, Wamola B, Olola CH, Kivaya E, Kokwaro G, et al. Pentoxifylline as an adjunct therapy in children with cerebral malaria. Malar J. 2010;9:368.","journal-title":"Malar J"},{"key":"7808_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12936-015-0946-2","volume":"14","author":"MT Hawkes","year":"2015","unstructured":"Hawkes MT, Conroy AL, Opoka RO, Hermann L, Thorpe KE, McDonald C, et al. Inhaled nitric oxide as adjunctive therapy for severe malaria: a randomized controlled trial. Malar J. 2015;14:421.","journal-title":"Malar J"},{"issue":"1","key":"7808_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12887-016-0719-2","volume":"16","author":"AL Conroy","year":"2016","unstructured":"Conroy AL, Hawkes M, Hayford K, Hermann L, McDonald CR, Sharma S, et al. Methemoglobin and nitric oxide therapy in Ugandan children hospitalized for febrile illness: results from a prospective cohort study and randomized double-blind placebo-controlled trial. BMC Pediatr. 2016;16(1):177.","journal-title":"BMC Pediatr"},{"issue":"5","key":"7808_CR19","doi-asserted-by":"publisher","first-page":"608","DOI":"10.4269\/ajtmh.1991.45.608","volume":"45","author":"CJ Hemmer","year":"1991","unstructured":"Hemmer CJ, Kern P, Holst FG, Nawroth PP, Dietrich M. Neither heparin nor acetylsalicylic acid influence the clinical course in human Plasmodium falciparum malaria: a prospective randomized study. Am J Trop Med Hyg. 1991;45(5):608\u201312.","journal-title":"Am J Trop Med Hyg"},{"issue":"12","key":"7808_CR20","doi-asserted-by":"publisher","first-page":"e1006022","DOI":"10.1371\/journal.ppat.1006022","volume":"12","author":"PA Swanson","year":"2016","unstructured":"Swanson PA, Hart GT, Russo MV, Nayak D, Yazew T, Pe\u00f1a M, et al. CD8+T cells induce fatal brainstem pathology during cerebral malaria via luminal antigen-specific engagement of brain vasculature. PLoS Pathog. 2016;12(12):e1006022.","journal-title":"PLoS Pathog"},{"key":"7808_CR21","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.3389\/fimmu.2019.01747","volume":"10","author":"V Barrera","year":"2019","unstructured":"Barrera V, Haley MJ, Strangward P, Attree E, Kamiza S, Seydel KB, et al. Comparison of CD8(+) T cell accumulation in the brain during human and murine cerebral malaria. Front Immunol. 2019;10:1747.","journal-title":"Front Immunol"},{"issue":"3","key":"7808_CR22","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI135510","volume":"130","author":"L R\u00e9nia","year":"2020","unstructured":"R\u00e9nia L, Grau GER, Wassmer SC. CD8+ T cells and human cerebral malaria: a shifting episteme. J Clin Invest. 2020;130(3):1109\u201311.","journal-title":"J Clin Invest"},{"issue":"3","key":"7808_CR23","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1172\/JCI133474","volume":"130","author":"BA Riggle","year":"2020","unstructured":"Riggle BA, Manglani M, Maric D, Johnson KR, Lee MH, Neto OLA, et al. CD8+ T cells target cerebrovasculature in children with cerebral malaria. J Clin Invest. 2020;130(3):1128\u201338.","journal-title":"J Clin Invest"},{"issue":"42","key":"7808_CR24","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1516544112","volume":"112","author":"EB Gordon","year":"2015","unstructured":"Gordon EB, Hart GT, Tran TM, Waisberg M, Akkaya M, Kim AS, et al. Targeting glutamine metabolism rescues mice from late-stage cerebral malaria. Proc Natl Acad Sci U S A. 2015;112(42):13075\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"51","key":"7808_CR25","doi-asserted-by":"publisher","first-page":"E12024","DOI":"10.1073\/pnas.1812909115","volume":"115","author":"BA Riggle","year":"2018","unstructured":"Riggle BA, Sinharay S, Schreiber-Stainthorp W, Munasinghe JP, Maric D, Prchalova E, et al. MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice. Proc Natl Acad Sci U S A. 2018;115(51):E12024\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"7808_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1056\/NEJMoa1400116","volume":"372","author":"KB Seydel","year":"2015","unstructured":"Seydel KB, Kampondeni SD, Valim C, Potchen MJ, Milner DA, Muwalo FW, et al. Brain swelling and death in children with cerebral malaria. N Engl J Med. 2015;372(12):1126\u201337.","journal-title":"N Engl J Med"},{"issue":"6","key":"7808_CR27","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/1097-0142(195711\/12)10:6<1138::AID-CNCR2820100608>3.0.CO;2-K","volume":"10","author":"GB Magill","year":"1957","unstructured":"Magill GB, Myers WP, Reilly HC, Putnam RC, Magill JW, Sykes MP, et al. Pharmacological and initial therapeutic observations on 6-diazo-5-oxo-1-norleucine (DON) in human neoplastic disease. Cancer. 1957;10(6):1138\u201350.","journal-title":"Cancer"},{"issue":"5","key":"7808_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/00000421-198210000-00014","volume":"5","author":"G Lynch","year":"1982","unstructured":"Lynch G, Kemeny N, Casper E. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma. Am J Clin Oncol. 1982;5(5):541\u20133.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"7808_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/00000421-198304000-00009","volume":"6","author":"J Rubin","year":"1983","unstructured":"Rubin J, Hineman V, Moertel CG, Schutt AJ, Hahn RG. A phase II study of alanosine in advanced large bowel carcinoma. Am J Clin Oncol. 1983;6(2):191\u20133.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"7808_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/BF00216936","volume":"8","author":"RH Earhart","year":"1990","unstructured":"Earhart RH, Amato DJ, Chang AY, Borden EC, Shiraki M, Dowd ME, et al. Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas. Invest New Drugs. 1990;8(1):113\u20139.","journal-title":"Invest New Drugs"},{"key":"7808_CR31","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1200\/jco.2008.26.15_suppl.2533","volume":"26","author":"C Mueller","year":"2008","unstructured":"Mueller C, Al-Batran SE, Jaeger E, Schmidt B, Bausch M, Unger C, et al. A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors. J Clin Oncol. 2008;26:2533.","journal-title":"J Clin Oncol"},{"key":"7808_CR32","unstructured":"Kovach JS, Eagan RT, Powis G, Rubin J, Creagan ET, Moertel CG. Phase I and pharmacokinetic studies of DON. Cancer Treat Rep. 1981;65(11\u201312):1031\u20141036. Available from: http:\/\/europepmc.org\/abstract\/MED\/7296548."},{"issue":"1","key":"7808_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/BF00262746","volume":"21","author":"MP Sullivan","year":"1988","unstructured":"Sullivan MP, Nelson JA, Feldman S, Van Nguyen B. Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. Cancer Chemother Pharmacol. 1988;21(1):78\u201384.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"7808_CR34","first-page":"1247","volume":"64","author":"RB Sklaroff","year":"1980","unstructured":"Sklaroff RB, Casper ES, Magill GB, Young CW. Phase I study of 6-diazo-5-oxo-L-norleucine (DON). Cancer Treat Rep. 1980;64(12):1247\u201351.","journal-title":"Cancer Treat Rep"},{"issue":"5","key":"7808_CR35","first-page":"1215","volume":"66","author":"RH Earhart","year":"1982","unstructured":"Earhart RH, Koeller JM, Davis HL. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses. Cancer Treat Rep. 1982;66(5):1215\u20137.","journal-title":"Cancer Treat Rep"},{"issue":"4","key":"7808_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/BF00170760","volume":"3","author":"A Rahman","year":"1985","unstructured":"Rahman A, Smith FP, Luc PT, Woolley PV. Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON). Invest New Drugs. 1985;3(4):369\u201374.","journal-title":"Invest New Drugs"},{"issue":"3","key":"7808_CR37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1172\/JCI104057","volume":"39","author":"AI Grayzel","year":"1960","unstructured":"Grayzel AI, Seegmiller JE, Love E. Suppression of uric acid synthesis in the gouty human by the use of 6-diazo-5-oxo-L-norleucine. J Clin Invest. 1960;39(3):447\u201354.","journal-title":"J Clin Invest"},{"key":"7808_CR38","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0025-7125(16)33879-2","volume":"45","author":"MC Li","year":"1961","unstructured":"Li MC. Management of choriocarcinoma and related tumors of uterus and testis. Med Clin North Am. 1961;45:661\u201376.","journal-title":"Med Clin North Am"},{"key":"7808_CR39","first-page":"83","volume":"18","author":"MP Sullivan","year":"1962","unstructured":"Sullivan MP, Beatty ECJ, Hyman CB, Murphy ML, Pierce MI, Severo NC. A comparison of the effectiveness of standard dose 6-mercaptopurine, combination 6-mercaptopurine and DON, and high-loading 6-mercaptopurine therapies in treatment of the acute leukemias of childhood: results of a coperative study. Cancer Chemother reports. 1962;18:83\u201395.","journal-title":"Cancer Chemother reports"},{"issue":"8","key":"7808_CR40","first-page":"1665","volume":"66","author":"RT Eagan","year":"1982","unstructured":"Eagan RT, Frytak S, Nichols WC, Creagan ET, Ingle JN. Phase II study on DON in patients with previously treated advanced lung cancer. Cancer Treat Rep. 1982;66(8):1665\u20136.","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"7808_CR41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12936-018-2355-9","volume":"17","author":"DG Postels","year":"2018","unstructured":"Postels DG, Wu X, Li C, Kaplan PW, Seydel KB, Taylor TE, et al. Admission EEG findings in diverse paediatric cerebral malaria populations predict outcomes. Malar J. 2018;17(1):208.","journal-title":"Malar J"},{"key":"7808_CR42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jpeds.2018.07.075","volume":"203","author":"NF O\u2019Brien","year":"2018","unstructured":"O\u2019Brien NF, Mutatshi Taty T, Moore-Clingenpeel M, Bodi Mabiala J, Mbaka Pongo J, Ambitapio Musungufu D, et al. Transcranial doppler ultrasonography provides insights into neurovascular changes in children with cerebral malaria. J Pediatr. 2018;203:116-124.e3.","journal-title":"J Pediatr"},{"key":"7808_CR43","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. 2017. Available from: https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf, https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/daids-adverse-event-grading-tables."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07808-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07808-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07808-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T08:11:10Z","timestamp":1706256670000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07808-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7808"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07808-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was initially approved by the National Health Sciences Research Committee in Malawi (20\/04\/2676) and the George Washington University IRB in the US (6017270069166886) on 28 May 2021. Written informed consent is obtained from all adult participants and parents\/guardians of pediatric participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"87"}}